These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 16076519)

  • 1. Validation of Haber's Rule (dose x time = constant) in rats and mice for monochloroacetic acid and 2,3,7,8-tetrachlorodibenzo-p-dioxin under conditions of kinetic steady state.
    Saghir SA; Lebofsky M; Pinson DM; Rozman KK
    Toxicology; 2005 Nov; 215(1-2):48-56. PubMed ID: 16076519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NTP toxicology and carcinogenesis studies of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague-Dawley rats (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2006 Jan; (520):4-246. PubMed ID: 16628245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of monochloroacetic acid at subtoxic and toxic doses in rats after single oral and dermal administrations.
    Saghir SA; Rozman KK
    Toxicol Sci; 2003 Nov; 76(1):51-64. PubMed ID: 12915718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of monochloroacetic acid in adult male rats after intravenous injection of a subtoxic and a toxic dose.
    Saghir SA; Fried K; Rozman KK
    J Pharmacol Exp Ther; 2001 Feb; 296(2):612-22. PubMed ID: 11160650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-based duration adjustments for the effects of inhaled trichloroethylene on rat visual function.
    Boyes WK; Bercegeay M; Ali JS; Krantz T; McGee J; Evans M; Raymer JH; Bushnell PJ; Simmons JE
    Toxicol Sci; 2003 Nov; 76(1):121-30. PubMed ID: 12915717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dependent pharmacokinetics of 1-(2-deoxy-beta-D- ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridine.
    Khalili P; Naimi E; Sun WY; Knaus EE; Wiebe LI
    Biopharm Drug Dispos; 2003 Dec; 24(9):385-95. PubMed ID: 14689467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developmental phase alters dosimetry-teratogenicity relationship for 2-methoxyethanol in CD-1 mice.
    Terry KK; Elswick BA; Stedman DB; Welsch F
    Teratology; 1994 Mar; 49(3):218-27. PubMed ID: 8059429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated cancer risk of dioxins to humans using a bioassay and physiologically based pharmacokinetic model.
    Maruyama W; Aoki Y
    Toxicol Appl Pharmacol; 2006 Jul; 214(2):188-98. PubMed ID: 16443251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final report of the safety assessment of Alcohol Denat., including SD Alcohol 3-A, SD Alcohol 30, SD Alcohol 39, SD Alcohol 39-B, SD Alcohol 39-C, SD Alcohol 40, SD Alcohol 40-B, and SD Alcohol 40-C, and the denaturants, Quassin, Brucine Sulfate/Brucine, and Denatonium Benzoate.
    Cosmetic Ingredient Review Expert Panel
    Int J Toxicol; 2008; 27 Suppl 1():1-43. PubMed ID: 18569160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NTP Technical Report on the comparative toxicity studies of allyl acetate (CAS No. 591-87-7), allyl alcohol (CAS No. 107-18-6) and acrolein (CAS No. 107-02-8) administered by gavage to F344/N rats and B6C3F1 mice.
    Irwin RD
    Toxic Rep Ser; 2006 Jul; (48):1-73, A1-H10. PubMed ID: 17160105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final amended report on the safety assessment of Methylparaben, Ethylparaben, Propylparaben, Isopropylparaben, Butylparaben, Isobutylparaben, and Benzylparaben as used in cosmetic products.
    Int J Toxicol; 2008; 27 Suppl 4():1-82. PubMed ID: 19101832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed acute toxicity of 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin (HpCDD), after oral administration, Obeys Haber's rule of inhalation toxicology.
    Rozman KK
    Toxicol Sci; 1999 May; 49(1):102-9. PubMed ID: 10367347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
    Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs.
    Boothe DM; Perkins J
    J Vet Pharmacol Ther; 2008 Dec; 31(6):544-53. PubMed ID: 19000278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of time as a quantifiable variable of toxicity and the experimental conditions when Haber's c x t product can be observed: implications for therapeutics.
    Rozman KK; Doull J
    J Pharmacol Exp Ther; 2001 Mar; 296(3):663-8. PubMed ID: 11181890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
    Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
    Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.